Pharmaceutical Executive Daily: September 29, 2025

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today’s Pharmaceutical Executive Daily, we cover the impact of Novo Nordisk layoffs on its hometown in Denmark, GSK’s appointment of Luke Miels as its next CEO, and the FDA’s approval of Regeneron’s Evkeeza for children with homozygous familial hypercholesterolemia.

In Denmark, the town surrounding Novo Nordisk’s headquarters is bracing for the impact of significant layoffs as part of the company’s global restructuring. The cuts are expected to reshape the local economy, where Novo serves as both the largest employer and a central driver of community investment. While Novo continues to grow internationally on the strength of its GLP-1 portfolio, the restructuring underscores the company’s efforts to manage costs and shift resources toward high-demand areas, even as local communities absorb the consequences.

In leadership news, GSK has named Luke Miels as its next chief executive officer. Currently serving as chief commercial officer, Miels will succeed Emma Walmsley and is expected to bring a sharper commercial edge to the company’s strategy. Known for his focus on execution and market performance, Miels’ appointment comes at a time when GSK is pushing to strengthen its pipeline and accelerate growth. Investors and analysts will be watching closely to see how his leadership reshapes priorities across vaccines, oncology, and specialty medicines.

And finally, the FDA has expanded approval of Regeneron’s Evkeeza to include children as young as five with homozygous familial hypercholesterolemia, an ultra-rare genetic condition that causes extremely high cholesterol levels from birth. Previously approved for patients aged 12 and older, the expansion provides younger children with access to a first-in-class therapy that can significantly reduce LDL cholesterol. Physicians hailed the approval as a critical step in improving outcomes for families managing this life-threatening disorder.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.